Servicio de Oncología Médica, Complejo Hospitalario Universitario de Santiago de Compostela, Travesía de Choupana s/n. 15706 Santiago de Compostela, Spain.
Anticancer Res. 2013 Feb;33(2):717-23.
To evaluate the efficacy and safety of erlotinib plus capecitabine for metastatic pancreatic cancer.
This was a multicenter, uncontrolled, phase II trial. Patients with untreated metastatic pancreatic cancer received oral capecitabine at 1,000 mg/m(2) twice daily on days 1-14, of a 21-day treatment cycle; and oral erlotinib at 150 mg daily.
Thirty-two patients were enrolled. The overall response rate (ORR) was 6%, with a median time to treatment failure of 2.1 months. The median follow-up was 7.6 months. The median progression-free survival was 2.1 months and median overall survival was 4.3 months. The one-year survival rate was 22%. Major grade 1 and 2 non-hematological toxicities were skin rash (34%), asthenia (31%) and diarrhea (31%). Grade 3 hematological toxicity was <13%. No grade 4 toxicities were detected. None of the patients died due to treatment toxicity.
The combination of capecitabine with erlotinib is an active regimen with a favorable safety profile for patients with metastatic pancreatic cancer.
评估厄洛替尼联合卡培他滨治疗转移性胰腺癌的疗效和安全性。
这是一项多中心、非对照、Ⅱ期临床试验。未经治疗的转移性胰腺癌患者接受卡培他滨口服，剂量为 1000mg/m2，每日 2 次，第 1-14 天；同时口服厄洛替尼，剂量为 150mg/d。
共纳入 32 例患者。总体缓解率（ORR）为 6%，中位无进展生存期为 2.1 个月。中位随访时间为 7.6 个月。中位无进展生存期为 2.1 个月，中位总生存期为 4.3 个月。1 年生存率为 22%。主要的 1 级和 2 级非血液学毒性为皮疹（34%）、乏力（31%）和腹泻（31%）。3 级血液学毒性<13%。未发生 4 级毒性。无患者因治疗毒性而死亡。
卡培他滨联合厄洛替尼治疗转移性胰腺癌具有较好的疗效和安全性。
